Sartorius Acquires Cell Culture Specialist Xell AG.

MANews-(C)2009-2021

German life science company Sartorius, through its subgroup Sartorius Stedim Biotech, has acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany, the company said.

Xell AG develops, produces, and markets media and feed supplements for cell cultures, especially for manufacturing viral vectors that are used in gene therapeutics and vaccines.

Beyond these media, the company offers various analytical services for characterizing, screening and quantifying media components, as well as for optimizing media composition.

Xell AG has so far been privately owned, employs around 35 people, and is expected to generate sales revenue of approximately EUR 5m at strong growth rates and a substantial two-digit EBITDA margin for the full year of 2021.

Recently, major capacity expansion was completed at the company's headquarters. The contractual parties agreed on a purchase price of around 50 m euros in addition to two earn--out components contingent upon the achievement of defined revenue targets in 2022 to 2025.

The Sartorius Group is a international partner of life science research and the biopharmaceutical industry.

...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT